Skip to content

BioNTech Share Price Gains on EUA Request for its Covid-19 Vaccine

Nigel Firth
Nigel Frith trader
Updated 21 Nov 2020

Practice Stock Tradingr
Covid-19 vaccine

Shares of BioNTech SE (NASDAQ: BNTX) gained nearly 10% Friday on news that a request for Emergency Use Authorization (EUA) will be submitted

Pfizer and BioNTech applied for the EUA with an aim to have it approved in early December. In this case, the first vaccines could eventually be deployed to high-risk groups by the middle to end of December.

“Filing in the U.S. represents a critical milestone in our journey to deliver a COVID-19 vaccine to the world and we now have a more complete picture of both the efficacy and safety profile of our vaccine, giving us confidence in its potential,” said Dr. Albert Bourla, Pfizer Chairman and CEO.

“We look forward to the upcoming Vaccines and Related Biological Products Advisory Committee discussion and continue to work closely with the FDA and regulatory authorities worldwide to secure authorization of our vaccine candidate as quickly as possible.”

As for Europe, two companies plan to seek conditional approval in Europe in the second half of December. Two companies said they will be ready to distribute the vaccine within hours after authorization.

BioNTech share price gained after confirming EUA request in the US November 2020

BioNTech share price soared nearly 10% to $104.07.


Nigel Firth
Nigel has been in the regulated financial services industry for nearly a decade, has previously owned a financial brokerage and has written many times for sites relating to personal finance and trading.